Rewind Therapeutics

Rewind Therapeutics is developing novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other myelin-related diseases. In close collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3), Axxam S.p.A. and a world-class academic network, Rewind Therapeutics aspires to advance innovative first-in-class therapies to the clinic. Rewind Therapeutics is based in Leuven, Belgium.

Team Member
more about
Cheryl Zimberlin
Investment Director
Latest News Entry
2023/01/25
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

2018/10/03
Rewind Therapeutics appoints leading neuroscience drug developer Ian J. Reynolds as Chief Executive Officer

Rewind Therapeutics (“Rewind”), a private Belgian biotech company developing innovative first-in-class therapies for myelin-related diseases announces the appointment of Ian J. Reynolds as its Chief Executive Officer (CEO)

2018/01/04
Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies
all portfolio news